A J&J veteran highlights listening to address overlooked maternal-fetal needs

[pressmaster/Adobe Stock]

With nearly 20 years of experience at Johnson & Johnson, Cynthia Accuosti Jones now spearheads the company’s pioneering maternal-fetal medicine group tackling unmet needs in high-risk pregnancies. As vice president of global commercial strategy for autoantibody and maternal fetal health, she spotlights listening as the driver for patient impact. “You can’t have empathy if you don’t listen to people and it’s incredible how much people just need to be listened to,” Jones emphasized, underscoring the importance of addressing the often-neglected area of maternal health.

Jones’ longtime interest in healthcare stemmed from a desire to help people. She considered nursing but ultimately pursued finance and international business at Georgetown, building on childhood analytical skills tracking her father’s stocks. That experience piqued her interest in financial markets and data analysis. She…

Read more
  • 0

How a J&J exec found her calling in autoantibody drug development

Katie Abouzahr

Dr. Katie Abouzahr’s career, which began in the wards of the UK’s National Health Service (NHS) before extending into management consulting, paved the way for her leadership of autoantibody and maternal fetal medicine programs at Johnson & Johnson. “It’s not a typical pharma executive’s straight line path,” she acknowledged. “Careers can often be jungle gyms as opposed to ladders that you climb one rung at a time. It’s always a mixture of opportunity, timing, serendipity, and persistence.”

Those qualities helped pave the way for her current focus on autoantibody-based conditions marked by high unmet need. Drawing on her experience across clinical medicine, consulting, and drug development, Abouzahr focuses on advancing medicines for autoimmune and autoantibody-driven diseases, which are marked by high unmet need. The broader immunology area is a central …

Read more
  • 0